Who Is Mariano Barbacid? Scientist Behind Shock Breakthrough That Wiped Out Pancreatic Cancer

For decades, pancreatic cancer has been one of medicine's most feared diagnoses. Aggressive, fast moving, and stubbornly resistant to treatment, it has claimed lives with ruthless efficiency.

Now, the name Mariano Barbacid is echoing far beyond scientific circles. His latest work is being hailed as one of the most important cancer breakthroughs in years, offering a glimmer of hope against a disease that has defied progress for decades.

Who Is Mariano Barbacid

Mariano Barbacid was born on 4 October 1949 and built his career at the cutting edge of cancer genetics. He earned his PhD from the Universidad Complutense de Madrid in 1974 before heading to the United States for postdoctoral training at the National Cancer Institute. It was there that his career took a historic turn.

In 1982, Barbacid isolated the first human oncogene, known as HRAS, from bladder cancer cells. The discovery proved that cancer is driven by specific genetic mutations, fundamentally changing how scientists understand the disease. It cemented his reputation as a pioneer and placed him at the centre of modern cancer biology.

After years in academia, Barbacid moved into industry, serving as vice president of oncology drug discovery at Bristol Myers Squibb from 1988 to 1998. He later returned to Spain to found the National Cancer Research Centre, known as CNIO, where he served as director until 2011 and continues to lead the Experimental Oncology Group.

Why Pancreatic Cancer Has Defied Treatment For So Long

Pancreatic cancer, particularly pancreatic ductal adenocarcinoma, is among the deadliest forms of the disease. In Spain alone, more than 10,000 cases are diagnosed each year. Because symptoms often appear late, most patients are diagnosed at advanced stages. The five-year survival rate remains below 10%.

For decades, chemotherapy offered little improvement. The first targeted drugs arrived only in 2021, focusing on KRAS, a gene mutated in about 90% of pancreatic cancers. While promising at first, these drugs quickly lost effectiveness as tumours adapted and became resistant.

Barbacid has spent much of his career studying KRAS and building animal models to understand how pancreatic cancer survives treatment. His latest work directly tackles the problem of resistance that has crippled previous therapies.

The Triple Therapy That Changed Everything In Mice

In January 2026, Barbacid and his team published their findings in the journal PNAS. Instead of blocking KRAS at a single point, they attacked the cancer pathway at three separate links, making it far harder for tumours to adapt.

The triple therapy combined daraxonrasib, a RAS ON inhibitor, afatinib, an approved lung cancer drug, and SD36, a protein degrader targeting STAT3. Tested across three mouse models, the results were extraordinary. Tumours regressed completely and did not return for more than 200 days. Crucially, the treatment was well tolerated, with no significant toxic effects.

Barbacid likened the strategy to fixing a beam at three points instead of one. By cutting off the cancer's escape routes, resistance failed to develop. For a disease where treatments usually stop working within months, this was a dramatic shift.

Hope, Caution, And What Comes Next

Despite the excitement, Barbacid has been careful to temper expectations. He has stressed that the team is not yet ready to move into human clinical trials. Optimising the drug combination for patients will take time, and success in mice does not guarantee the same outcome in people.

Still, the implications are enormous. Experts say the study opens the road to combination therapies that could finally improve survival in pancreatic cancer. After half a century of limited progress, the field is beginning to change direction.

Barbacid's achievements have already earned him some of the highest honours in science, including the Echegaray Medal, the Santiago Ramón y Cajal National Research Prize, and membership in the US National Academy of Sciences. Yet his latest work may prove to be his most impactful.

For now, Mariano Barbacid stands as a symbol of renewed hope. While a cure for pancreatic cancer in humans is not yet here, his breakthrough has shown that even the deadliest tumours are not invincible.